Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HRAS | P01112 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29171479 | 0.70 | FNTA (0.46) | HRASKRASFNTAFNTBPGGT1B | |
| SCHEMBL29171480 | 0.70 | FNTA (0.46) | HRASKRASFNTAFNTBPGGT1B | |
| SCHEMBL21877258 | 0.66 | FNTA (0.61) | HRASKRASFNTAFNTBPGGT1B | |
| SCHEMBL18041272 | 0.66 | FNTA (0.61) | HRASKRASFNTAFNTBPGGT1B | |
| SCHEMBL18041271 | 0.66 | FNTA (0.61) | HRASKRASFNTAFNTBPGGT1B | |
| SCHEMBL29171478 | 0.63 | FNTA (0.79) | HRASKRASFNTAFNTBPGGT1B | |
| SCHEMBL7131913 | 0.61 | HRH3 (0.49) | HRH3HRH4 | |
| SCHEMBL6930996 | 0.61 | HRH3 (0.49) | HRH3HRH4 | |
| SCHEMBL25456036 | 0.60 | TAAR1 (0.57) | HRH3POLBKMT2AHRH4 | |
| SCHEMBL27395190 | 0.59 | HRH3 (0.81) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138835-A1 | FORMULATIONS OF BRINCIDOFOVIR | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138835-A1 | FORMULATIONS OF BRINCIDOFOVIR | SAMHD1, UGT2B7, HPRT1 | HRH3 1510/4885MEN1 3368/4885ALDH1A1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.